Shiloh
Editor, Senior Moderator
Source: https://news.trust.org/item/20210813050819-c58at/
Peru study finds Sinopharm COVID vaccine 50.4% effective against infections
by Reuters
Friday, 13 August 2021 05:07 GMT
By Marcelo Rochabrun and Roxanne Liu
LIMA/BEIJING, Aug 13 (Reuters) - A two-dose COVID-19 vaccine from China's Sinopharm was 50.4% effective in preventing infections in health workers in Peru when it was seeing a surge in cases fuelled by virus variants, and booster shots can be considered, a study found.
The study https://repositorio.ins.gob.pe/xmlu.../Efectividad de la.pdf?sequence=1&isAllowed=y involving Sinopharm's BBIBP-CorV vaccine, which looked at data from February through June at a time when Peru was fighting a brutal second-wave of infections fuelled by the Lambda and Gamma variants of the coronavirus, was conducted on nearly 400,000 frontline health workers in live conditions.
Most of the health workers received two doses of the vaccine.
"The efficacy to prevent infection is not high and this is something to consider once a high percentage of the population receives its two doses, (the) moment when boosters can be considered to optimize the protection of frontline health workers," said the study published last week from scientists at Peru's National Institute of Health and two other research institutes.
The vaccine, however, was 94% effective at preventing deaths after two doses, it added...
Peru study finds Sinopharm COVID vaccine 50.4% effective against infections
by Reuters
Friday, 13 August 2021 05:07 GMT
By Marcelo Rochabrun and Roxanne Liu
LIMA/BEIJING, Aug 13 (Reuters) - A two-dose COVID-19 vaccine from China's Sinopharm was 50.4% effective in preventing infections in health workers in Peru when it was seeing a surge in cases fuelled by virus variants, and booster shots can be considered, a study found.
The study https://repositorio.ins.gob.pe/xmlu.../Efectividad de la.pdf?sequence=1&isAllowed=y involving Sinopharm's BBIBP-CorV vaccine, which looked at data from February through June at a time when Peru was fighting a brutal second-wave of infections fuelled by the Lambda and Gamma variants of the coronavirus, was conducted on nearly 400,000 frontline health workers in live conditions.
Most of the health workers received two doses of the vaccine.
"The efficacy to prevent infection is not high and this is something to consider once a high percentage of the population receives its two doses, (the) moment when boosters can be considered to optimize the protection of frontline health workers," said the study published last week from scientists at Peru's National Institute of Health and two other research institutes.
The vaccine, however, was 94% effective at preventing deaths after two doses, it added...